A unique case of transitional cell carcinoma of renal pelvis in a patient with Lynch syndrome

Sanwal, Chandra; Nooruddin, Karim; Nguyen‐Anh, Tuan; Bailey, Michael; Moon, A.S.; Guzmán, Antonio Aguilar; Phillips, Jacqueline K.

doi:10.5455/im.56055

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the literature search and the study selection process are shown in the PRISMA flow diagram 29 (figure 1). A total of 1745 studies were screened, of which 110 were included: 2 clinical trials, 35 36 86 retrospective studies, 27 28 37-120 13 case reports [121][122][123][124][125][126][127][128][129][130][131][132][133] and 9 review articles [134][135][136][137][138][139][140][141][142] (online supplemental table S1). Among all included studies, sex was reported in 13 445 patients (73.4% male; 26.6% female).…”

Section: Study Selection and Clinicopathological Characteristicsmentioning

confidence: 99%

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis

Chandran,

Iannantuono,

Atiq

et al. 2024

bmjonc

View full text Add to dashboard Cite

BackgroundMismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) occur in a subset of cancers and have been shown to confer sensitivity to immune checkpoint inhibition (ICI); however, there is a lack of prospective data in urothelial carcinoma (UC).Methods and analysisWe performed a systematic review to estimate the prevalence of dMMR and MSI-H in UC, including survival and clinical outcomes. We searched for studies published up to 26 October 2022 in major scientific databases. We screened 1745 studies and included 110. Meta-analyses were performed if the extracted data were suitable.ResultsThe pooled weighted prevalences of dMMR in bladder cancer (BC) and upper tract UC (UTUC) were 2.30% (95% CI 1.12% to 4.65%) and 8.95% (95% CI 6.81% to 11.67%), respectively. The pooled weighted prevalences of MSI-H in BC and UTUC were 2.11% (95% CI 0.82% to 5.31%) and 8.36% (95% CI 5.50% to 12.53%), respectively. Comparing localised versus metastatic disease, the pooled weighted prevalences for MSI-H in BC were 5.26% (95% CI 0.86% to 26.12%) and 0.86% (95% CI 0.59% to 1.25%), respectively; and in UTUC, they were 18.04% (95% CI 13.36% to 23.91%) and 4.96% (95% CI 2.72% to 8.86%), respectively. Cumulatively, the response rate in dMMR/MSI-H metastatic UC treated with an ICI was 22/34 (64.7%) compared with 1/9 (11.1%) with chemotherapy.ConclusionBoth dMMR and MSI-H occur more frequently in UTUC than in BC. In UC, MSI-H occurs more frequently in localised disease than in metastatic disease. These biomarkers may predict sensitivity to ICI in metastatic UC and resistance to cisplatin-based chemotherapy.

show abstract